Pharmacovigilance Market Size, Share & Trends Analysis Report By Product Life Cycle, By Service Provider, By Type, By Therapeutic Area, By Process Flow, By End-use, And Segment Forecasts, 2020 - 2027

Table of Content

Chapter 1 Research Methodology & Scope
1.1 Market Segmentation & Scope
1.1.1 Service Provider
1.1.2 Type
1.1.3 Product Life Cycle
1.1.4 Process Flow
1.1.5 Therapeutic area
1.1.6 End-use
1.1.7 Regional Scope
1.1.8 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database:
1.3.2 GVR’s Internal Database
1.3.3 Secondary sources
1.3.4 Primary Research:
1.3.5 Details of Primary Research
1.3.5.1 Data for primary interviews in North America
1.3.5.2 Data for Primary Interviews in Europe
1.3.5.3 Data for Primary Interviews in APAC
1.3.5.4 Data for Primary Interviews in Latin America
1.3.5.5 Data for Primary Interviews in MEA
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.1.1 Approach 1: Commodity Flow Approach
1.7 List of Secondary Sources
1.8 List of Abbreviations
1.9 Market Definitions
1.9.1 Product Life Cycle
1.9.1.1 Preclinical
1.9.1.2 Phase I
1.9.1.3 Phase II
1.9.1.4 Phase III
1.9.1.5 Phase IV
1.9.2 Type of Methods Outlook
1.9.2.1 Spontaneous reporting
1.9.2.2 Intensified ADR Reporting
1.9.2.3 Targeted Spontaneous Reporting
1.9.2.4 Cohort Event Monitoring
1.9.2.5 EHR Mining
1.9.3 Service Providers Outlook
1.9.3.1 In-house
1.9.3.2 Outsourcing
1.9.4 End-use Outlook
1.9.4.1 Pharmaceuticals & Biotechnology Companies
1.9.4.2 Medical Device Manufacturers
1.10 Report Objectives
1.10.1 Objective 1
1.10.2 Objective 2
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Pharmacovigilance Market Outlook, 2016-2027 (USD Million)
2.3 Segment Outlook
2.4 Competitive Outlook
Chapter 3 Pharmacovigilance Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent market analysis
3.1.2 Ancillary market Analysis
3.2 Penetration & Growth Prospect Mapping
3.3 Pharmacovigilance Market Dynamics
3.3.1 Market driver analysis
3.3.1.1 Growing drug consumption and drug development rates
3.3.1.2 Increasing incidence of ADR and drug toxicity
3.3.1.3 Increasing trend of outsourcing pharmacovigilance services
3.3.1.4 Increasing externalization of clinical trial studies by large pharmaceutical and biopharmaceutical companies
3.3.1.5 Increasing regulatory burden on manufacturers
3.3.1.6 Introduction of technologically advanced software services
3.3.1.7 Constantly rising investment on R&D by healthcare companies
3.3.1.8 Partnerships and collaborations between market players
3.3.2 Market restraint analysis
3.3.2.1 Shortage of skilled labor
3.3.2.2 Expensive technology for small and mid-sized player
3.3.2.3 Lack of recognition
3.3.2.4 Scarcity of integration standards
3.3.3 Industry Challenges
3.4 Pharmacovigilance Market Analysis Tools: Porters
3.5 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
3.6 Value Chain Analysis
3.6.1 Preclinical
3.6.2 Clinical
3.6.3 PMA
3.7 Mapping of Life Cycle Against Service Offering And Their Demand
3.8 Regulatory Framework
3.8.1 List of regulatory bodies by Country
3.9 Pharmacovigilance: Organization Structure Introduction
3.10 Pricing Models
3.10.1 Drug Safety Budget Allocation By Activities
3.10.2 By Development phase
3.10.3 By Therapeutic area
3.10.4 Pricing Level
3.10.4.1 Case processing
3.10.4.2 ADR Reporting
3.10.4.3 Medical writing
3.10.4.4 Drug safety management
3.11 Technology Timeline Overview
3.11.1 Changing Technology & Adoption
3.11.1.1 Social Media
3.11.1.2 Literature screening
3.11.1.3 Automation and AI
3.11.1.4 Big data analytics in PV
Chapter 4 COVID-19 Impact Analysis
4.1 COVID-19 Outbreak
4.1.1 Challenges for safety reporting activities
4.2 Demand Analysis
4.2.1 Product Pipeline Analysis, by Stage for COVID-19
4.3 Recent Developments & Strategic Outcomes
4.3.1 Regulatory requirements/changes due to covid-19
4.3.2 Strategies implemented by companies
4.3.2.1 IQVIA
4.3.2.2 PARAXEL International Corporation
4.3.2.3 Bioclinica
4.3.2.4 Pharmaceutical Product Development (PPD)
4.3.2.5 IBM Corporation
4.3.2.6 ICON, plc
4.3.2.7 PRA Health Sciences
4.3.2.8 Covance Inc
4.3.2.9 ArisGlobal
4.3.2.10 Linical Accelovance
4.3.2.11 Laboratory Corporation of America Holdings
Chapter 5 Pharmacovigilance Market: Service provider Estimates & Trend Analysis
5.1 Service Provider Market Share Analysis, 2019 & 2027
5.2 Service Provider Dashboard
5.2.1 In House
5.2.1.1 In house market estimates and forecasts, 2016 - 2027 (USD Million)
5.2.2 Contract Outsourcing
5.2.2.1 Contract outsourcing market estimates and forecasts, 2016 - 2027 (USD Million)
Chapter 6 Pharmacovigilance Market: Type Estimates & Trend Analysis
6.1 Type Market Share Analysis, 2019 & 2027
6.2 Type Dashboard
6.2.1 Spontaneous Reporting
6.2.1.1 Spontaneous Reporting market estimates and forecasts, 2016 - 2027 (USD Million)
6.2.2 Intensified ADR Reporting
6.2.2.1 Intensified ADR Reporting market estimates and forecasts, 2016 - 2027 (USD Million)
6.2.3 Targeted Spontaneous Reporting
6.2.3.1 Targeted spontaneous reporting market estimates and forecasts, 2016 - 2027 (USD Million)
6.2.4 Cohort Event Monitoring (CEM)
6.2.4.1 CEM market estimates and forecasts, 2016 - 2027 (USD Million)
6.2.5 EHR Mining
6.2.5.1 EHR Mining market estimates and forecasts, 2016 - 2027 (USD Million)
Chapter 7 Pharmacovigilance Market: Product Life Cycle Estimates & Trend Analysis
7.1 Product Life Cycle Market Share Analysis, 2019 & 2027
7.2 Product Dashboard
7.2.1 Preclinical
7.2.1.1 Preclinical market estimates and forecasts, 2016 - 2027 (USD Million)
7.2.2 Phase I
7.2.2.1 Phase I market estimates and forecasts, 2016 - 2027 (USD Million)
7.2.3 Phase II
7.2.3.1 Phase II market estimates and forecasts, 2016 - 2027 (USD Million)
7.2.4 Phase III
7.2.4.1 Phase III market estimates and forecasts, 2016 - 2027 (USD Million)
7.2.5 Phase IV
7.2.5.1 Phase IV market estimates and forecasts, 2016 - 2027 (USD Million)
Chapter 8 Pharmacovigilance Market: Process Flow Estimates & Trend Analysis
8.1 Process Flow Market Share Analysis, 2019 & 2027
8.2 Process Flow Dashboard
8.2.1 Case data management
8.2.1.1 Case data management market estimates and forecasts, 2016 - 2027 (USD Million)
8.2.1.2 Case logging
8.2.1.3 Case logging market estimates and forecasts, 2016 - 2027 (USD Million)
8.2.1.4 Case data analysis
8.2.1.5 Case data analysis market estimates and forecasts, 2016 - 2027 (USD Million)
8.2.1.6 Medical reviewing and reporting
8.2.1.7 Medical reviewing and reporting market estimates and forecasts, 2016 - 2027 (USD Million)
8.2.2 Signal detection
8.2.2.1 Signal detection market estimates and forecasts, 2016 - 2027 (USD Million)
8.2.2.2 Adverse Event Logging
8.2.2.3 Adverse Event Logging market estimates and forecasts, 2016 - 2027 (USD Million)
8.2.2.4 Adverse Event Analysis
8.2.2.5 Adverse Event Analysis market estimates and forecasts, 2016 - 2027 (USD Million)
8.2.2.6 Adverse Event Review & Reporting
8.2.2.7 Adverse Event Review & Reporting market estimates and forecasts, 2016 - 2027 (USD Million)
8.2.3 Risk Management System
8.2.3.1 Risk Management System market estimates and forecasts, 2016 - 2027 (USD Million)
8.2.3.2 Risk Evaluation System
8.2.3.3 Risk Evaluation System market estimates and forecasts, 2016 - 2027 (USD Million)
8.2.3.4 Risk Mitigation System
8.2.3.5 Risk Mitigation System market estimates and forecasts, 2016 - 2027 (USD Million)
Chapter 9 Pharmacovigilance Market: Therapeutic Area Estimates & Trend Analysis
9.1 Therapeutic Area Market Share Analysis, 2019 & 2027
9.2 Therapeutic Area Dashboard
9.2.1 Oncology
9.2.1.1 Oncology market estimates and forecasts, 2016 - 2027 (USD Million)
9.2.2 Neurology
9.2.2.1 Neurology market estimates and forecasts, 2016 - 2027 (USD Million)
9.2.3 Cardiology
9.2.3.1 Cardiology market estimates and forecasts, 2016 - 2027 (USD Million)
9.2.4 Respiratory systems
9.2.4.1 Respiratory systems market estimates and forecasts, 2016 - 2027 (USD Million)
9.2.5 Others
9.2.5.1 Others market estimates and forecasts, 2016 - 2027 (USD Million)
Chapter 10 Pharmacovigilance Market: End-Use Estimates & Trend Analysis
10.1 End-Use Market Share Analysis, 2019 & 2027
10.2 End-Use Dashboard
10.2.1 Pharmaceuticals
10.2.1.1 Pharmaceuticals market estimates and forecasts, 2016 - 2027 (USD Million)
10.2.2 Biotechnology Companies
10.2.2.1 Biotechnology companies market estimates and forecasts, 2016 - 2027 (USD Million)
10.2.3 Medical Device Manufacturers
10.2.3.1 Medical Device Manufacturers market estimates and forecasts, 2016 - 2027 (USD Million)
10.2.4 Others
10.2.4.1 Others market estimates and forecasts, 2016 - 2027 (USD Million)
Chapter 11 Pharmacovigilance Market: Regional Estimates & Trend Analysis by Segments
11.1 Regional Market Snapshot
11.2 Market Share Analysis by Country, 2019
11.2.1 North America
11.2.1.1 SWOT Analysis
11.2.2 Europe
11.2.2.1 SWOT Analysis
11.2.3 Asia Pacific
11.2.3.1 SWOT Analysis
11.2.4 Latin America
11.2.4.1 SWOT Analysis
11.2.5 MEA
11.2.5.1 SWOT Analysis
11.3 North America
11.3.1 North America Pharmacovigilance market estimates and forecasts, 2016 - 2027 (USD Million)
11.3.2 U.S.
11.3.2.1 U.S. Pharmacovigilance market estimates and forecasts, 2014 - 2026(USD Million)
11.3.3 Canada
11.3.3.1 Canada Pharmacovigilance market estimates and forecasts, 2014 - 2026(USD Million)
11.4 Europe
11.4.1 Europe Pharmacovigilance MARKET estimates and forecasts, 2016 - 2027 (USD Million)
11.4.2 U.K.
11.4.2.1 U.K. Pharmacovigilance market estimates and forecasts, 2014 - 2026(USD Million)
11.4.3 Germany
11.4.3.1 Germany Pharmacovigilance market estimates and forecasts, 2016 - 2027 (USD Million)
11.4.4 France
11.4.4.1 France Pharmacovigilance market estimates and forecasts, 2016 - 2027 (USD Million)
11.4.5 Italy
11.4.5.1 Italy Pharmacovigilance market estimates and forecasts, 2016 - 2027 (USD Million)
11.4.6 Spain
11.4.6.1 Spain pharmacovigilance market estimates and forecasts, 2016 - 2027 (USD Million)
11.4.7 Russia
11.4.7.1 Russia Pharmacovigilance market estimates and forecasts, 2016 - 2027 (USD Million)
11.5 Asia Pacific
11.5.1 Asia Pacific Pharmacovigilance market estimates and forecasts, 2016 - 2027 (USD Million)
11.5.2 Japan
11.5.2.1 Japan Pharmacovigilance market estimates and forecasts, 2016 - 2027 (USD Million)
11.5.3 China
11.5.3.1 China Pharmacovigilance market estimates and forecasts, 2016 - 2027 (USD Million)
11.5.4 India
11.5.4.1 India Pharmacovigilance market estimates and forecasts, 2016 - 2027 (USD Million)
11.6 Latin America
11.6.1 Latin America Pharmacovigilance market estimates and forecasts, 2016 - 2027 (USD Million)
11.6.2 Brazil
11.6.2.1 Brazil Pharmacovigilance market estimates and forecasts, 2016 - 2027 (USD Million)
11.6.3 Mexico
11.6.3.1 Mexico Pharmacovigilance market estimates and forecasts, 2016 - 2027 (USD Million)
11.7 MEA
11.7.1 MEA Pharmacovigilance market estimates and forecasts, 2016 - 2027 (USD Million)
11.7.2 South Africa
11.7.2.1 South Africa Pharmacovigilance market estimates and forecasts, 2016 - 2027 (USD Million)
11.7.3 Kingdom of Saudi Arabia
11.7.3.1 Kingdom of Saudi Arabia Pharmacovigilance market estimates and forecasts, 2016 - 2027 (USD Million)
Chapter 12 Competitive Outlook
12.1 Market Participation Categorization
12.2 Public Companies
12.2.1 Company market position analysis
12.2.2 Company Market Share
12.3 Private Companies
12.3.1 List of key emerging companies
12.4 Consolidation Trends
12.5 Potential Customers
Chapter 13 Company Profiles
13.1 Accenture
13.1.1 Company overview
13.1.2 Service benchmarking
13.1.3 Organization structure & Team Composition
13.1.3.1 Team composition
13.1.4 Financial performance
13.1.5 R&D expenditure
13.1.6 Strategic initiatives
13.1.7 SWOT Analysis
13.2 Clinquest Group B.V. (Linical Americas)
13.2.1 Company overview
13.2.2 Service benchmarking
13.2.3 Organization structure & Team Composition
13.2.3.1 Team composition
13.2.4 Financial performance
13.2.5 Strategic initiatives
13.2.6 SWOT Analysis
13.3 IQVIA
13.3.1 Company overview
13.3.2 Service benchmarking
13.3.3 Organization structure & Team Composition
13.3.3.1 Team composition
13.3.4 Financial performance
13.3.5 Strategic initiatives
13.3.6 SWOT Analysis
13.4 Cognizant
13.4.1 Company overview
13.4.2 Service benchmarking
13.4.3 Organization structure & Team Composition
13.4.3.1 Team composition
13.4.4 Financial performance
13.4.5 Strategic initiatives
13.4.6 SWOT Analysis
13.5 Laboratory Corporation of America Holdings
13.5.1 Company overview
13.5.2 Service benchmarking
13.5.3 Organization structure & Team Composition
13.5.3.1 Team composition
13.5.4 Financial performance
13.5.5 Strategic initiatives
13.5.6 SWOT Analysis
13.6 IBM Corporation
13.6.1 Company overview
13.6.2 Service benchmarking
13.6.3 Organization structure & Team Composition
13.6.3.1 Team composition
13.6.4 Financial performance
13.6.5 R&D expenditure
13.6.6 Strategic initiatives
13.6.7 SWOT Analysis
13.7 ArisGlobal
13.7.1 Company overview
13.7.2 Service benchmarking
13.7.3 Organization structure & Team Composition
13.7.3.1 Team composition
13.7.4 Financial performance
13.7.5 Strategic initiatives
13.7.6 SWOT Analysis
13.8 ICON Plc.
13.8.1 Company overview
13.8.2 Service benchmarking
13.8.3 Organization structure & Team Composition
13.8.3.1 Team composition
13.8.4 Financial performance
13.8.5 Strategic initiatives
13.8.6 SWOT Analysis
13.9 Capgemini
13.9.1 Company overview
13.9.2 Service benchmarking
13.9.3 Organization structure & Team Composition
13.9.3.1 Team composition
13.9.4 Financial performance
13.9.5 Strategic initiatives
13.9.6 SWOT Analysis
13.10 ITClinical
13.10.1 Company overview
13.10.2 Service benchmarking
13.10.3 Organization structure & Team Composition
13.10.3.1 Team composition
13.10.4 Financial performance
13.10.5 SWOT Analysis
13.11 TAKE Solutions
13.11.1 Company overview
13.11.2 Service benchmarking
13.11.3 Organization structure & Team Composition
13.11.3.1 Team composition
13.11.4 Financial performance
13.11.5 Strategic initiatives
13.11.6 SWOT Analysis
13.12 PAREXEL International Corporation
13.12.1 Company overview
13.12.2 Service benchmarking
13.12.3 Organization structure & Team Composition
13.12.3.1 Team composition
13.12.4 Financial performance
13.12.5 Strategic initiatives
13.12.6 SWOT Analysis
13.13 BioClinica, Inc.
13.13.1 Company overview
13.13.2 Service benchmarking
13.13.3 Organization structure & Team Composition
13.13.3.1 Team composition
13.13.4 Financial performance
13.13.5 Strategic initiatives
13.13.6 SWOT Analysis
13.14 Wipro Limited
13.14.1 Company overview
13.14.2 Service benchmarking
13.14.3 Organization structure & Team Composition
13.14.3.1 Team composition
13.14.4 Financial performance
13.14.5 R&D expenditure
13.14.6 Strategic initiatives
13.14.7 SWOT Analysis
13.15 UNITED BIOSOURCE CORPORATION
13.15.1 Company overview
13.15.2 Service benchmarking
13.15.3 Organization structure & Team Composition
13.15.3.1 Team composition
13.15.4 Financial performance
13.15.5 Strategic initiatives
13.15.6 SWOT Analysis
13.16 FMD K&L
13.16.1 Company overview
13.16.2 Service benchmarking
13.16.3 Organization structure & Team Composition
13.16.3.1 Team composition
13.16.4 Financial performance
13.16.5 Strategic initiatives
13.16.6 SWOT Analysis
Chapter 14 Winning Strategies
14.1 Key Winning/Scoring Criteria
14.1.1 By categories
14.1.1.1 Pharmaceuticals
14.1.1.2 Biotech companies
14.1.1.3 Medical device companies
14.2 Key Vendor Selection Factors
14.2.1 By Category
14.2.2 BY Company size
14.2.2.1 Key Takeaways
Chapter 15 Switching Cost Analysis